ArticleBiosensors & bioelectronics2022
Horseradish peroxidase-triggered direct in situ fluorescent immunoassay platform for sensing cardiac troponin I and SARS-CoV-2 nucleocapsid protein in serum.
Article in Biosensors & bioelectronics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 52 citations in OpenAlex.
- Recent approaches in the sensing strategy for the detection of cardiovascular disease biomarkers.RSC advances · 2026Review
- A Portable Personal Glucometer-Based Immunoassay Platform for Horseradish Peroxidase-Related Biomarker Detection.Biosensors · 2026Article
- Overcoming HRP/TMB/HBiosensors · 2026Article
- Article
- Iron oxide nanoparticles: biosynthesis, peroxidase-like activity, and biosafety.Applied microbiology and biotechnology · 2025Review
- Development of an immunoassay lollipop using syringe-autoinjected visual distance readout for point-of-care testing.Analytical and bioanalytical chemistry · 2025Article
- Research progress on nanomaterial-empowered electrochemical biosensors for the detection of cardiac troponin I.RSC advances · 2025Review
- Article
- Cardiac Troponin I Biosensors: Innovations in Real-Time Diagnosis of Cardiovascular Diseases.Analytical science advances · 2025Review
- Highly sensitive digital detection of SARS-CoV-2 nucleocapsid protein through single-molecule counting.Analytical and bioanalytical chemistry · 2023Article
- Methods for detecting of cardiac troponin I biomarkers for myocardial infarction using biosensors: a narrative review of recent research.Journal of thoracic disease · 2023Review
- Beads- and oil-free single molecule assay with immuno-rolling circle amplification for detection of SARS-CoV-2 from saliva.Biosensors & bioelectronics · 2023Article
- A photoelectrochemical immunosensor based on magnetic all-solid-state Z-scheme heterojunction for SARS-CoV-2 nucleocapsid protein detection.Sensors and actuators. B, Chemical · 2023Article
- Magnetic/fluorescent dual-modal lateral flow immunoassay based on multifunctional nanobeads for rapid and accurate SARS-CoV-2 nucleocapsid protein detection.Analytica chimica acta · 2022Article
- Impedimetric Detection Based on Label-Free Immunoassay Developed for Targeting Spike S1 Protein of SARS-CoV-2.Diagnostics (Basel, Switzerland) · 2022Article
- Multiplex Label-Free Kinetic Characterization of Antibodies for Rapid Sensitive Cardiac Troponin I Detection Based on Functionalized Magnetic Nanotags.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Direct in situ fluorescent enzyme-linked immunosorbent assay (ELISA) is rarely investigated and reported. Herein, a direct in situ high-performance HRP-labeled fluorescent immunoassay platform was constructed. The platform was developed based on a rapid in situ fluorogenic reaction between Polyethyleneimine (PEI) and p-Phenylenediamine (PPD) analogues to generate fluorescent copolymer nanoparticles (FCNPs). The formation mechanism of FCNPs was found to be the oxidation of •OH radicals, which was further proved by nitrogen protection and scavenger of •OH radicals. Meantime, the fluorescence wavelength of FCNPs could be adjusted from 471 to 512 nm by introducing various substitution groups into the PPD structure. Using cardiac troponin I (cTnI) and SARS-CoV-2 nucleocapsid protein (N-protein) as the model antigens, the proposed fluorescent ELISA exhibited a wide dynamic range of 5-180 ng/mL and a low limit of detection (LOD) of 0.19 ng/mL for cTnI, and dynamic range of 0-120 ng/mL and a LOD of 0.33 ng/mL for SARS-CoV-2 N protein, respectively. Noteworthy, the proposed method was successful applied to evaluate the cTnI and SARS-CoV-2 N protein levels in serum with satisfied results. Therefore, the proposed platform paved ways for developing novel fluorescence-based HRP-labeled ELISA technologies and broadening biomarker related clinical diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.